SWISSE Ultiboost High Strength Krill Oil has successfully accessed the AUST L(A) pathway.
The product is now formally listed in the ARTG as AUST L(A) 417392.
The successful use of the AUST L(A) pathway is the outcome of a collaboration between Swisse and CSIRO, Australia's national science agency, highlighting the vitamin and mineral supplements supplier's dedication to providing, it claims, research-backed products to consumers.
Swisse says it "adheres to the highest quality standards, and helps consumers understand the complementary medicines space, through education on specific indications".
Unlike listed medicines, the AUST L(A) pathway requires a premarket assessment of evidence.
As such, a clinical trial published in the American Journal of Clinical Nutrition demonstrated that Swisse Ultiboost High Strength Krill Oil (RRP: $35.99) was effective in improving knee pain, stiffness, and physical function in individuals with mild-to-moderate knee osteoarthritis.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Sep 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Sep 23
